Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

Investigational topical androgen-receptor degrader (PROTAC), developed by Kintor Pharmaceutical

GT20029 — evidence

What has been published, classified by the kind of document it is. This is not a protocol, not a score, and not a recommendation for use.

Evidence overview

1 record in this file

  • CLINICAL TRIAL1

Research areas. Investigational hair-follicle research.

Publication span. 2025.

What we know

    Editorial reading of the records below, labelled as Therapept analysis. How records are built

    What remains uncertain

      Regulatory notes

      Investigational

      • No approved product in Drugs@FDA as of this review.
      • Phase 2 trial NCT06692465 randomised 180 Chinese adult men with androgenetic alopecia for 12 weeks and is registered as completed.
      • The Phase 2 report describes significant improvements in target-area hair count in some dose groups versus placebo, with adverse events mostly mild and similar across groups.
      • No public CAS number, molecular formula or pharmacopoeial identity standard was identified for GT20029. That is a documentation gap, not evidence about the molecule's activity.
      • Androgen-receptor degradation is the proposed mechanism; Phase 3 confirmation and long-term safety are not available.

      Regulatory status describes how a substance is classified. It is not a safety assessment of any particular material.

      Studies and documents

      1. CLINICAL TRIAL2025Phase 2 multicentre, randomised, double-blind, placebo-controlled trial

        Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a phase 2 study

        Hu R, et al.Journal of Dermatological Treatment

        Population
        Chinese adult men with androgenetic alopecia (Hamilton-Norwood IIIv–V)
        Sample
        n = 180
        Objective
        To evaluate the efficacy and safety of topical GT20029, an androgen-receptor degrader, in men with androgenetic alopecia.
        Endpoint investigated
        Target-area hair count and target-area hair weight, with adverse events

        Study design

        Phase
        Phase 2
        Duration
        12 weeks
        Intervention, as the source describes it
        Topical GT20029 solution at several dose levels and application frequencies, compared with placebo
        Comparator
        Placebo
        Primary endpoint
        Efficacy and safety of topical GT20029 in androgenetic alopecia
        Registry
        NCT06692465

        This describes the published study design. It is not a usage or dosing recommendation.

        The authors report statistically significant improvements in target-area hair count in some GT20029 groups versus placebo over 12 weeks, and a significant improvement in target-area hair weight in one treatment group. Adverse-event incidence was similar across groups and events were mostly mild.

        Limitations. One Phase 2 trial in Chinese men over 12 weeks. It does not establish Phase 3-level efficacy, long-term safety or superiority to any approved treatment, and no public identity standard for the drug substance was identified.

        DOI 10.1080/09546634.2025.2574304Hu et al., J Dermatolog Treat (2025) — PubMed 41328006Reviewed 13 November 2026

      Last reviewed 13 November 2026 · Compiled by Therapept Editorial · How these records are built